- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01565694
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The NDO often occurs in patients with spina bifida or other spinal cord damage where the bladder muscle contracts more than normal during filling. These patients often have an inability to void, so that catheterization is required to empty the bladder.
The medicine being tested in this study is called solifenacin succinate. Solifenacin tablets are given to adults for the treatment of overactive bladder. A new liquid suspension has been developed to treat children and adolescents in this and other studies.
The efficacy and safety of the solifenacin suspension was investigated. The take-up and length of time that the solifenacin suspension stays in the body was also investigated during this study. Effectiveness was measured by urodynamics (the filling and emptying of the bladder) and the urine volumes during catheterization together with the diary responses relating to the number of incontinence episodes or incontinence free days.
Safety assessments included analysis of the blood and urine, review of the electrocardiogram (ECG), ultrasound of the kidney, simple memory and understanding tests (cognitive function) and the ability to see near and far objects (visual accommodation).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gent, Belgium, 9000
- Site BE3201
-
-
-
-
-
Campinas, Brazil, 13060-803
- Site BR5507
-
Campinas, Brazil, 13083-887
- Site BR5504
-
Curitiba, Brazil, 80240-060
- Site BR5506
-
Porto Alegre, Brazil, 90035-903
- Site BR5503
-
-
São Paulo
-
Sao Jose do Rio Preto, São Paulo, Brazil, 15090-000
- Site BR5505
-
-
-
-
-
Aarhus, Denmark, 8200
- Site DK4501
-
-
-
-
-
Miskolc, Hungary, 3526
- Site HU3602
-
-
-
-
-
Seoul, Korea, Republic of, 110744
- Site KR8207
-
Seoul, Korea, Republic of, 120752
- Site KR8201
-
-
-
-
-
Leon, Mexico, 37000
- Site MX5203
-
Mexico City, Mexico, C.P. 06700
- Site MX5205
-
-
-
-
-
Manila, Philippines, 1015
- Site PH6301
-
Quezon City, Philippines, 1101
- Site PH6302
-
-
-
-
-
Gdansk, Poland, 80-952
- Site PL4803
-
Gdansk, Poland, 80803
- Site PL4805
-
Warszawa, Poland, 04-730
- Site PL4801
-
-
-
-
-
Ankara, Turkey, 6100
- Site TR9003
-
Izmir, Turkey, 35100
- Site TR9002
-
-
-
-
New York
-
Tarrytown, New York, United States, 10591
- Site US1008
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229-3039
- Site US1010
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented diagnosis of NDO, confirmed by urodynamics
- Practicing clean intermittent catheterization (CIC)
- Currently on treatment with an antimuscarinic drug
Exclusion Criteria:
- Known genitourinary condition (other than NDO) that may cause incontinence
- Bladder augmentation surgery
- Current Faecal impaction
- Electro-stimulation therapy within 2 weeks prior to screening and at any time during the study
- Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention
- Reflux grade 3 or 4
- Current urinary tract infection (UTI)
- Subject has severe renal impairment (glomerular filtration rate < 30 ml/min)
- Subject has severe hepatic impairment (Child-Pugh score > 9).
- Subject has received intra-vesical botulinum toxin within 9 months prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Solifenacin succinate
Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg. After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52). |
Oral suspension administered once a day via syringe.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC)
Time Frame: Baseline and Week 24
|
During urodynamic assessments, the bladder was filled until voiding/leakage begins, or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
MCC is the maximum bladder capacity reached during filling cystometry before either leakage or pain/discomfort was observed.
|
Baseline and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Last Possible Titration Step in Maximum Cystometric Capacity
Time Frame: Baseline, Week 9 or Week 12
|
During urodynamic assessments, the bladder was filled until voiding/leakage begins, or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
MCC is the maximum bladder capacity reached during filling cystometry before either leakage or pain/discomfort was observed.
Based on study requirements, the last possible titration step was Week 9 for participants enrolled under versions 1.0 and 1.1 and Week 12 under later versions.
|
Baseline, Week 9 or Week 12
|
Change From Baseline in Bladder Compliance
Time Frame: Baseline and Week 24
|
Bladder compliance gives an indication of the elasticity of the bladder wall and was calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder.
|
Baseline and Week 24
|
Change From Baseline in Bladder Volume (mL) Until First Detrusor Contraction > 15 cmH2O as a Percentage of Expected Bladder Capacity (EBC)
Time Frame: Baseline and Week 24
|
Change from baseline in the bladder volume was calculated using urodyanamic assessments.
During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the subject experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
If no detrusor contraction of at least 15 cmH2O occurs, the bladder volume was imputed with MCC.
|
Baseline and Week 24
|
Change From Baseline in Bladder Volume at 30 cmH2O Detrusor Pressure
Time Frame: Baseline and Week 24
|
Bladder volumes at 30 cm H2O detrusor pressure was calculated using the urodynamic assessments.
During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the participants experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
|
Baseline and Week 24
|
Change From Baseline in Bladder Volume at 40 cmH2O Detrusor Pressure
Time Frame: Baseline and Week 24
|
Bladder volumes at 40 cm H2O detrusor pressure were calculated using urodynamic assessments.
During urodynamic assessments, the bladder is filled until voiding/leakage begins, or until it is stopped because either the subject experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
|
Baseline and Week 24
|
Change From Baseline in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until End of Bladder Filling
Time Frame: Baseline to Week 24
|
Change from baseline in number of overactive detrusor contractions until end of bladder filling was measured by urodynamic testing.
If leakage occurred, the "Detrusor pressure at leakage" was recorded otherwise the volume of fluid instilled into the bladder was recorded.
|
Baseline to Week 24
|
Change From Baseline in Detrusor Pressure at the End of Bladder Filling
Time Frame: Baseline to Week 24
|
The bladder was filled until voiding/leakage began or until it was stopped because either the participant experiences pain or discomfort or 135% of expected bladder capacity for age has been reached.
Pressure was recorded for an extra 5 minutes after leakage began or the end of bladder-filling, whichever is sooner.
|
Baseline to Week 24
|
Change From Baseline in Average Catheterized Volume Per Catheterization
Time Frame: Baseline to Week 24
|
The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days are concurrent.
|
Baseline to Week 24
|
Change From Baseline in Maximum Catheterized Volume
Time Frame: Baseline to Week 24
|
The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent.
The maximum value was calculated separately for each measuring day and the mean of these two values was used.
|
Baseline to Week 24
|
Change From Baseline in Average First Morning Catheterized Volume
Time Frame: Baseline to Week 24
|
The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent.
|
Baseline to Week 24
|
Change From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
Time Frame: Baseline to Week 24
|
The mean of the number of incontinence episodes per 24h was calculated as the mean over the valid diary days in the 7-day diary.
|
Baseline to Week 24
|
Change From Baseline in Number of Dry (Incontinence-Free) Days Per 7 Days
Time Frame: Baseline to Week 24
|
The number of incontinence-free days was calculated from the 7-day micturition diary.
|
Baseline to Week 24
|
Change From Baseline in Number of Dry (Incontinence-Free) Nights Per 7 Days
Time Frame: Baseline to Week 24
|
The number of incontinence-free nights was calculated from the 7-day micturition diary.
|
Baseline to Week 24
|
Change From Baseline in Quality of Life [QoL] (PinQ Questionnaire Score)
Time Frame: Baseline to Week 24
|
Pediatric Incontinence Questionnaire (PinQ) is a 20-item questionnaire addressing quality of life for participants with bladder disorders.
Each question was answered on a scale from 0 (no, never) to 4 (all the time).
The total score ranged from 0 to 80, with higher scores indicated more impact on the quality of life.
|
Baseline to Week 24
|
Number of Participants With Adverse Events
Time Frame: Baseline to End of Study Visit (Week 52)
|
A treatment-emergent adverse event (TEAE) was defined as an adverse event observed after starting administration of the first dose of study medication on Day 1.
All adverse events collected within 7 days after taking the last dose of study drug were counted as a TEAE.
|
Baseline to End of Study Visit (Week 52)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F, Newgreen D. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect. 2020 Dec;8(6):e00684. doi: 10.1002/prp2.684.
- Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E, Snijder R, Stroosma O, Verheggen F, Newgreen D, Bosman B, Vande Walle J. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol. 2020 Apr;16(2):180.e1-180.e8. doi: 10.1016/j.jpurol.2019.12.012. Epub 2019 Dec 27.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder, Overactive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Solifenacin Succinate
Other Study ID Numbers
- 905-CL-047
- 2011-000330-11 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurogenic Detrusor Overactivity
-
Seoul National University HospitalCompletedNeurogenic Bladder | Detrusor Overactivity | Detrusor UnderactivityKorea, Republic of
-
PfizerCompletedNeurogenic Detrusor OveractivityBelgium
-
PfizerCompletedUrinary Bladder, NeurogenicJapan
-
Astellas Pharma Europe B.V.CompletedNeurogenic Detrusor OveractivityBelgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
-
Astellas Pharma IncCompletedOveractive Bladder | Neurogenic Detrusor OveractivityBelgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
-
Astellas Pharma Europe B.V.CompletedPediatric | Neurogenic Detrusor OveractivityUnited States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
-
Novartis PharmaceuticalsTerminatedNeurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, SpasticNetherlands, Germany, Switzerland
-
University College, LondonRoyal National Orthopaedic Hospital NHS TrustRecruitingSpinal Cord Injuries | Neurogenic Bladder | Neurogenic Detrusor Overactivity | Neurogenic Bladder DysfunctionUnited Kingdom
-
PfizerCompletedOveractive Bladder | Neurogenic Detrusor OveractivityUnited States
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Neurogenic Detrusor OveractivityDenmark, Poland
Clinical Trials on Solifenacin succinate
-
Astellas Pharma Europe B.V.CompletedPediatric | Neurogenic Detrusor OveractivityUnited States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin SuccinateUnited States
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveSweden, United Kingdom, Belgium, Denmark
-
Astellas Pharma Europe B.V.CompletedUrinary Bladder, OveractiveBelgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
-
Center Eugene MarquisTerminated
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of Solifenacin SuccinateUnited States
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Stamford HospitalWithdrawnOveractive Bladder | Urge Incontinence | Urinary UrgeUnited States
-
Beni-Suef UniversityCompletedVoiding DisordersEgypt
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveUnited States